Key data
Open—
From 52W high—
Volume—
Market cap—
P/E (TTM)—
P/S (TTM)—
Div yield—
Key data
Open
—
From 52W high
—
Volume
—
Market cap
—
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
—
P/E (TTM)
—
RSI (14)
—
MomentumView details →
1D Return
—
YTD Return
—
SummaryUpdated Sep 1, 2026
DBV Technologies S.A. (NASDAQ:DBVT) is a French clinical-stage biopharmaceutical company founded in 2002 and headquartered in Montrouge, France. The company went public on NASDAQ in October 2014 and specializes in developing epicutaneous immunotherapy treatments, which deliver therapeutic compounds through the skin rather than through injections or oral medications. DBV Technologies is primarily focused on developing treatments for food allergies, with its lead product candidate being Viaskin Peanut for treating peanut allergies in children and toddlers.
Latest newsMore news →
DBV Technologies S.A. reported cash and cash equivalents of $165.7 million as of September 30, 2026, which it said would fund operations into the third quarter of 2027.2d agoDBV Technologies S.A. announced that it will host an investor conference call and live webcast on October 28, 2026, at 5:00 p.m. ET to review its third-quarter financial results and provide a business update.3d agoDBV Technologies submitted a Biologics License Application to the U.S. FDA for its VIASKIN Peanut Patch for children aged 4-7 years, requesting Priority Review.31d ago